진행성 핵상마비 치료 시장 : 전략적 인사이트 및 예측(2026-2035년)

Global Progressive Supranuclear Palsy Treatment Market is projected to register a strong CAGR during the forecast period (2026-2035).

Progressive Supranuclear Palsy (PSP) is a rare and progressive neurodegenerative disorder characterized by postural instability, gait impairment, ocular motor dysfunction, cognitive decline, speech difficulties, swallowing disorders, and motor impairment. The disease is classified as a tauopathy, in which abnormal accumulation of tau protein leads to neuronal degeneration and functional decline. PSP typically develops later in life and progresses rapidly, often resulting in severe disability and reduced quality of life. Currently, treatment options primarily focus on symptom management and supportive care, as no widely established disease-modifying therapies are available. This substantial unmet need continues to drive research, innovation, and investment throughout the treatment landscape.

The PSP treatment market is undergoing a transition from symptomatic disease management toward targeted therapeutic intervention. Growing understanding of disease mechanisms, improvements in diagnostic capabilities, and increasing participation in clinical development programs are creating opportunities for novel therapies that may alter disease progression. Pharmaceutical companies, biotechnology firms, academic research centers, and patient advocacy organizations are actively collaborating to accelerate treatment development and improve patient outcomes.

Market Drivers

Rising Focus on Disease-Modifying Therapies

One of the most significant drivers of market growth is the increasing emphasis on therapies designed to modify disease progression rather than simply alleviate symptoms. Researchers are targeting key pathological mechanisms including tau aggregation, neuroinflammation, lysosomal dysfunction, and neuronal degeneration.

Advances in antisense oligonucleotides, monoclonal antibodies, immunotherapies, and neuroprotective agents are expanding the therapeutic pipeline and creating new opportunities for long-term disease management.

Growing Understanding of Tau Pathology

Scientific advances in tau biology have significantly improved understanding of PSP disease mechanisms. As tau accumulation is recognized as the central pathological hallmark of PSP, treatment developers are increasingly focusing on therapies that directly target tau-related pathways.

The growing body of evidence supporting tau-directed interventions is strengthening confidence in future therapeutic innovation and encouraging additional investment across the sector.

Expansion of Orphan Drug Development Programs

PSP qualifies as a rare disease in major pharmaceutical markets, enabling developers to benefit from orphan drug incentives such as market exclusivity, regulatory support, accelerated review programs, and development assistance.

These incentives are reducing barriers to entry and encouraging greater participation from biotechnology companies and specialty pharmaceutical developers.

Advancements in Biomarker Development

The development of imaging biomarkers, fluid biomarkers, neurofilament light chain testing, and advanced neurological assessment tools is improving disease diagnosis and patient stratification.

Enhanced biomarker capabilities support earlier diagnosis, more efficient clinical trials, and improved monitoring of treatment responses, contributing to the advancement of the PSP treatment market.

Market Restraints

Absence of Approved Disease-Modifying Therapies

Despite significant research activity, treatment options remain largely limited to symptomatic management. Existing therapies provide only modest improvements in certain symptoms and do not significantly alter disease progression.

The lack of established disease-modifying treatments continues to represent one of the most important challenges facing the market.

Diagnostic Challenges and Misdiagnosis

PSP shares several clinical features with Parkinson's disease and other movement disorders, resulting in frequent misdiagnosis during early disease stages.

Diagnostic uncertainty can delay treatment initiation, limit clinical trial recruitment, and affect overall patient management strategies.

Limited Patient Population

As a rare neurodegenerative disorder, PSP affects a relatively small patient population. This can create challenges related to patient recruitment, clinical trial execution, commercial viability, and epidemiological assessment.

Smaller patient populations may also increase development costs and prolong research timelines.

Technology and Segment Insights

The global progressive supranuclear palsy treatment market can be segmented by therapy type, drug class, indication, route of administration, end user, distribution channel, and geography.

By therapy type, the market includes symptomatic therapies, disease-modifying therapies, and emerging therapies. Symptomatic therapies currently account for the largest share due to the absence of approved disease-modifying treatments. However, disease-modifying therapies are expected to experience the fastest growth as clinical development programs mature.

By drug class, the market includes small molecules, monoclonal antibodies, antisense oligonucleotides, peptide-based therapies, neuroprotective agents, and other emerging therapeutic modalities. Small molecules currently represent a major segment due to established development pathways and manufacturing scalability, while biologics and RNA-based therapies are gaining increasing attention.

By indication, the market includes PSP-Richardson syndrome, PSP-Parkinsonism, and other PSP variants. PSP-Richardson syndrome represents a significant treatment segment because it is the most widely recognized and frequently diagnosed clinical phenotype.

By route of administration, the market includes oral therapies, intravenous therapies, injectable therapies, and other delivery methods. Oral therapies currently dominate symptomatic management, while intravenous and injectable therapies are becoming increasingly important for advanced biologic and disease-modifying candidates.

By end user, the market includes hospitals, specialty neurology clinics, academic medical centers, rehabilitation facilities, and home healthcare providers. Specialty neurology centers and academic institutions play critical roles in diagnosis, treatment administration, and clinical research activities.

By distribution channel, the market includes hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies maintain a substantial share due to the specialized nature of neurological treatment and patient monitoring requirements.

Technological innovation is reshaping treatment development through artificial intelligence, biomarker-guided clinical trials, precision medicine approaches, digital health technologies, wearable monitoring devices, and advanced neuroimaging platforms. These technologies improve patient selection, treatment monitoring, endpoint assessment, and therapeutic development efficiency.

Geographically, North America represents the leading market due to advanced neurological research infrastructure, strong orphan drug development activity, extensive clinical trial programs, and supportive regulatory frameworks. Europe maintains a significant position supported by established rare disease policies and collaborative research networks. Asia-Pacific is emerging as a promising market due to expanding healthcare infrastructure, increasing disease awareness, growing clinical research participation, and rising investments in neurological care. Latin America and the Middle East & Africa are gradually improving access to specialized neurological services and rare disease treatment programs.

Competitive and Strategic Outlook

The competitive landscape is evolving as pharmaceutical companies, biotechnology firms, and research organizations pursue innovative therapies capable of addressing the underlying pathology of PSP. Companies are increasingly focusing on tau-targeted interventions, antisense oligonucleotides, monoclonal antibodies, neuroprotective agents, and immunotherapy platforms.

Strategic partnerships, licensing agreements, collaborative research initiatives, and platform-based clinical trial models are becoming increasingly common as stakeholders seek to accelerate development timelines and reduce scientific risk. Academic institutions and biotechnology companies continue to play a central role in advancing novel therapeutic concepts.

Pipeline diversification is strengthening the long-term outlook for the market. Multiple therapeutic mechanisms are being explored simultaneously, reducing reliance on any single approach and increasing the likelihood of future treatment breakthroughs. Companies that successfully demonstrate clinically meaningful slowing of disease progression are expected to gain significant competitive advantages in the future treatment landscape.

Conclusion

The global progressive supranuclear palsy treatment market is expected to experience sustained growth through 2031, supported by expanding scientific understanding of tau pathology, increasing orphan drug development activity, advances in biomarker technologies, and growing investment in disease-modifying therapies. While challenges related to diagnostic complexity, limited patient populations, and the absence of approved disease-modifying treatments remain significant, ongoing innovation across antisense therapies, monoclonal antibodies, neuroprotective agents, and precision medicine platforms is expected to transform the future treatment landscape. Continued collaboration among industry participants, academic institutions, and regulatory organizations will play a critical role in improving therapeutic options and outcomes for patients living with progressive supranuclear palsy.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Key Findings
• 1.3 Market Snapshot
• 1.4 Treatment Landscape Overview
• 1.5 Epidemiology Highlights
• 1.6 Pipeline Development Overview
• 1.7 Competitive Intelligence Summary
• 1.8 Future Market Outlook

2. Disease & Epidemiology Analysis

• 2.1 Progressive Supranuclear Palsy (PSP): Disease Overview
  • 2.1.1 Disease Definition
  • 2.1.2 Disease Pathophysiology
  • 2.1.3 Tau Protein Dysfunction and Neurodegeneration
  • 2.1.4 Disease Burden and Unmet Medical Needs
• 2.2 Disease Classification and Subtypes
  • 2.2.1 Richardson Syndrome (PSP-RS)
  • 2.2.2 PSP-Parkinsonism (PSP-P)
  • 2.2.3 PSP with Progressive Gait Freezing (PSP-PGF)
  • 2.2.4 PSP-Corticobasal Syndrome (PSP-CBS)
  • 2.2.5 PSP-Speech/Language Variant (PSP-SL)
  • 2.2.6 Other Clinical Variants
• 2.3 Risk Factors and Disease Progression
  • 2.3.1 Genetic Factors
  • 2.3.2 Age-Related Risk
  • 2.3.3 Environmental and Biological Factors
  • 2.3.4 Disease Progression Patterns
• 2.4 Global Epidemiology Analysis
  • 2.4.1 Prevalence Analysis
  • 2.4.2 Incidence Analysis
  • 2.4.3 Diagnosed Patient Population
  • 2.4.4 Treated Patient Population
  • 2.4.5 Gender-Based Epidemiology
  • 2.4.6 Age-Based Epidemiology
  • 2.4.7 Epidemiology Forecast
• 2.5 Diagnostic Landscape
  • 2.5.1 Clinical Diagnosis Pathway
  • 2.5.2 Imaging-Based Diagnosis
  • 2.5.3 Biomarker Development Trends
  • 2.5.4 Differential Diagnosis Challenges

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
  • 3.2.1 Rising Awareness of Rare Neurodegenerative Disorders
  • 3.2.2 Advancements in Tau-Targeted Therapeutics
  • 3.2.3 Increasing Clinical Research Activities
  • 3.2.4 Expansion of Rare Disease Funding Programs
• 3.3 Market Restraints
  • 3.3.1 Limited Approved Disease-Modifying Therapies
  • 3.3.2 Diagnostic Delays and Misdiagnosis
  • 3.3.3 Small Patient Population
  • 3.3.4 Clinical Development Challenges
• 3.4 Market Opportunities
  • 3.4.1 Emerging Biomarker Technologies
  • 3.4.2 Precision Medicine Approaches
  • 3.4.3 Novel Tau-Directed Therapeutics
  • 3.4.4 Strategic Collaborations and Licensing Agreements
• 3.5 Market Challenges
  • 3.5.1 Recruitment Challenges in Clinical Trials
  • 3.5.2 Long-Term Outcome Assessment
  • 3.5.3 Reimbursement and Access Barriers
• 3.6 Porter's Five Forces Analysis
  • 3.6.1 Threat of New Entrants
  • 3.6.2 Bargaining Power of Suppliers
  • 3.6.3 Bargaining Power of Buyers
  • 3.6.4 Threat of Substitutes
  • 3.6.5 Competitive Rivalry

4. Commercial & Market Access

• 4.1 Current Commercial Landscape
• 4.2 Treatment Adoption Trends
• 4.3 Pricing Analysis
• 4.4 Reimbursement Frameworks
• 4.5 Health Technology Assessment (HTA) Trends
• 4.6 Patient Access Programs
• 4.7 Rare Disease Incentive Programs
• 4.8 Market Access Challenges and Opportunities

5. Innovation & Pipeline Landscape

• 5.1 Pipeline Overview
• 5.2 Pipeline by Development Phase
  • 5.2.1 Discovery and Preclinical Stage
  • 5.2.2 Phase I Candidates
  • 5.2.3 Phase II Candidates
  • 5.2.4 Phase III Candidates
• 5.3 Pipeline by Mechanism of Action
  • 5.3.1 Tau Aggregation Inhibitors
  • 5.3.2 Tau Immunotherapies
  • 5.3.3 Microtubule Stabilizers
  • 5.3.4 Neuroprotective Therapies
  • 5.3.5 Anti-Inflammatory Approaches
  • 5.3.6 Genetic and RNA-Based Therapies
• 5.4 Pipeline by Modality
  • 5.4.1 Small Molecules
  • 5.4.2 Monoclonal Antibodies
  • 5.4.3 Antisense Oligonucleotides
  • 5.4.4 Gene-Based Therapies
  • 5.4.5 Cell-Based Therapies
• 5.5 Clinical Trial Landscape
  • 5.5.1 Ongoing Clinical Studies
  • 5.5.2 Completed Clinical Studies
  • 5.5.3 Terminated and Discontinued Programs
  • 5.5.4 Emerging Trial Designs
• 5.6 Intellectual Property and Innovation Trends
• 5.7 Strategic Collaborations, Licensing, and Partnerships

6. Treatment Landscape

• 6.1 Current Standard of Care
• 6.2 Treatment Algorithm
• 6.3 Symptomatic Treatment Landscape
  • 6.3.1 Levodopa-Based Therapies
  • 6.3.2 Dopaminergic Agents
  • 6.3.3 Antidepressants
  • 6.3.4 Botulinum Toxin Therapy
  • 6.3.5 Supportive and Rehabilitation Therapies
• 6.4 Disease-Modifying Therapy Development
• 6.5 Emerging Treatment Paradigms
• 6.6 Comparative Assessment of Available Therapeutic Options
• 6.7 Unmet Needs and Future Treatment Directions

7. Global Progressive Supranuclear Palsy Treatment Landscape Report Size & Forecast

• 7.1 Global Market Size Analysis (Historical)
• 7.2 Global Market Forecast
• 7.3 Epidemiology-Based Market Forecast Model
• 7.4 Revenue Forecast by Therapy Type
• 7.5 Revenue Forecast by Route of Administration
• 7.6 Revenue Forecast by Drug Type
• 7.7 Revenue Forecast by Region
• 7.8 Scenario Analysis
  • 7.8.1 Base Case Scenario
  • 7.8.2 Optimistic Scenario
  • 7.8.3 Conservative Scenario

8. Global Progressive Supranuclear Palsy Treatment Landscape Report Segmentation

• 8.1 By Therapy Type
  • 8.1.1 Symptomatic Therapies
  • 8.1.2 Disease-Modifying Therapies
  • 8.1.3 Others
• 8.2 By Drug Type
  • 8.2.1 Dopaminergic Agents
  • 8.2.2 Antidepressants
  • 8.2.3 Anticholinergic Agents
  • 8.2.4 Other Emerging Drug Classes
• 8.3 By Route of Administration
  • 8.3.1 Oral
  • 8.3.2 Intravenous
  • 8.3.3 Other Routes
• 8.3 By Care Setting
  • 8.3.1 Hospitals and Clinics
  • 8.3.2 Home Healthcare
  • 8.3.3 Others

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size and Growth
  • 9.1.2 Epidemiology Trends
  • 9.1.3 Demand Drivers
  • 9.1.4 Regional Regulatory Overview
  • 9.1.5 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Growth
  • 9.2.2 Epidemiology Trends
  • 9.2.3 Demand Drivers
  • 9.2.4 Regional Regulatory Overview
  • 9.2.5 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Growth
  • 9.3.2 Epidemiology Trends
  • 9.3.3 Demand Drivers
  • 9.3.4 Regional Regulatory Overview
  • 9.3.5 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Growth
  • 9.4.2 Epidemiology Trends
  • 9.4.3 Demand Drivers
  • 9.4.4 Regional Regulatory Overview
  • 9.4.5 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Growth
  • 9.5.2 Epidemiology Trends
  • 9.5.3 Demand Drivers
  • 9.5.4 Regional Regulatory Overview
  • 9.5.5 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Market Size
  • 10.1.2 Epidemiology
  • 10.1.3 Regulatory Framework
  • 10.1.4 Reimbursement Landscape
  • 10.1.5 Key Companies and Product Presence
• 10.2 Canada
  • 10.2.1 Market Size
  • 10.2.2 Epidemiology
  • 10.2.3 Regulatory Framework
  • 10.2.4 Reimbursement Landscape
  • 10.2.5 Key Companies and Product Presence
• 10.3 Germany
  • 10.3.1 Market Size
  • 10.3.2 Epidemiology
  • 10.3.3 Regulatory Framework
  • 10.3.4 Reimbursement Landscape
  • 10.3.5 Key Companies and Product Presence
• 10.4 United Kingdom
  • 10.4.1 Market Size
  • 10.4.2 Epidemiology
  • 10.4.3 Regulatory Framework
  • 10.4.4 Reimbursement Landscape
  • 10.4.5 Key Companies and Product Presence
• 10.5 France
  • 10.5.1 Market Size
  • 10.5.2 Epidemiology
  • 10.5.3 Regulatory Framework
  • 10.5.4 Reimbursement Landscape
  • 10.5.5 Key Companies and Product Presence
• 10.6 Italy
  • 10.6.1 Market Size
  • 10.6.2 Epidemiology
  • 10.6.3 Regulatory Framework
  • 10.6.4 Reimbursement Landscape
  • 10.6.5 Key Companies and Product Presence
• 10.7 Spain
  • 10.7.1 Market Size
  • 10.7.2 Epidemiology
  • 10.7.3 Regulatory Framework
  • 10.7.4 Reimbursement Landscape
  • 10.7.5 Key Companies and Product Presence
• 10.8 China
  • 10.8.1 Market Size
  • 10.8.2 Epidemiology
  • 10.8.3 Regulatory Framework
  • 10.8.4 Reimbursement Landscape
  • 10.8.5 Key Companies and Product Presence
• 10.9 Japan
  • 10.9.1 Market Size
  • 10.9.2 Epidemiology
  • 10.9.3 Regulatory Framework
  • 10.9.4 Reimbursement Landscape
  • 10.9.5 Key Companies and Product Presence
• 10.10 India
  • 10.10.1 Market Size
  • 10.10.2 Epidemiology
  • 10.10.3 Regulatory Framework
  • 10.10.4 Reimbursement Landscape
  • 10.10.5 Key Companies and Product Presence
• 10.11 South Korea
  • 10.11.1 Market Size
  • 10.11.2 Epidemiology
  • 10.11.3 Regulatory Framework
  • 10.11.4 Reimbursement Landscape
  • 10.11.5 Key Companies and Product Presence
• 10.12 Australia
  • 10.12.1 Market Size
  • 10.12.2 Epidemiology
  • 10.12.3 Regulatory Framework
  • 10.12.4 Reimbursement Landscape
  • 10.12.5 Key Companies and Product Presence
• 10.13 Brazil
  • 10.13.1 Market Size
  • 10.13.2 Epidemiology
  • 10.13.3 Regulatory Framework
  • 10.13.4 Reimbursement Landscape
  • 10.13.5 Key Companies and Product Presence
• 10.14 Mexico
  • 10.14.1 Market Size
  • 10.14.2 Epidemiology
  • 10.14.3 Regulatory Framework
  • 10.14.4 Reimbursement Landscape
  • 10.14.5 Key Companies and Product Presence
• 10.15 Saudi Arabia
  • 10.15.1 Market Size
  • 10.15.2 Epidemiology
  • 10.15.3 Regulatory Framework
  • 10.15.4 Reimbursement Landscape
  • 10.15.5 Key Companies and Product Presence
• 10.16 South Africa
  • 10.16.1 Market Size
  • 10.16.2 Epidemiology
  • 10.16.3 Regulatory Framework
  • 10.16.4 Reimbursement Landscape
  • 10.16.5 Key Companies and Product Presence

11. Regulatory & Policy Landscape

• 11.1 United States Regulatory Framework (FDA)
  • 11.1.1 Orphan Drug Designation Pathways
  • 11.1.2 Fast Track and Breakthrough Therapy Programs
  • 11.1.3 PSP Clinical Development Requirements
• 11.2 Europe Regulatory Framework (EMA)
  • 11.2.1 Orphan Medicinal Product Designation
  • 11.2.2 Centralized Approval Pathway
  • 11.2.3 Post-Marketing Requirements
• 11.3 Japan Regulatory Framework (PMDA)
  • 11.3.1 Rare Disease Drug Approval Framework
  • 11.3.2 Accelerated Review Pathways
• 11.4 India Regulatory Framework (CDSCO)
  • 11.4.1 Clinical Trial Approval Process
  • 11.4.2 Orphan Drug Provisions
• 11.5 China Regulatory Framework (NMPA)
  • 11.5.1 Rare Disease Drug Registration
  • 11.5.2 Priority Review Programs
• 11.6 Global Rare Disease Policy Landscape
• 11.7 Reimbursement and Access Regulations
• 11.8 Pharmacovigilance and Post-Marketing Surveillance

12. Competitive Landscape

• 12.1 Market Structure Analysis
• 12.2 Competitive Positioning Matrix
• 12.3 Pipeline Competitiveness Assessment
• 12.4 Strategic Development Activities
  • 12.4.1 Collaborations and Partnerships
  • 12.4.2 Licensing Agreements
  • 12.4.3 Mergers and Acquisitions
  • 12.4.4 Research Collaborations
• 12.5 Clinical Trial Competitiveness
• 12.6 Patent and Intellectual Property Assessment
• 12.7 SWOT Analysis
• 12.8 Benchmarking of Leading Developers

13. Company Profiles

• 13.1 Novartis AG
  • 13.1.1 Company Overview
  • 13.1.2 Neurology Portfolio
  • 13.1.3 Approved Products (Brand and Generic)
  • 13.1.4 Key Indications
  • 13.1.5 PSP and Tauopathy Pipeline Assets
  • 13.1.6 Clinical Development Status
  • 13.1.7 Strategic Outlook
• 13.2 Alzprotect
  • 13.2.1 Company Overview
  • 13.2.2 OXZ-002 and Related Programs
  • 13.2.3 Target Indications
  • 13.2.4 Clinical Development Status
  • 13.2.5 PSP Pipeline Strategy
• 13.3 Transposon Therapeutics
  • 13.3.1 Company Overview
  • 13.3.2 TPN-101 Program
  • 13.3.3 Mechanism of Action
  • 13.3.4 Clinical Development Status
  • 13.3.5 PSP Development Strategy
• 13.4 Ferrer
  • 13.4.1 Company Overview
  • 13.4.2 Neurology Portfolio
  • 13.4.3 Approved Products
  • 13.4.4 Pipeline Programs
  • 13.4.5 PSP Development Activities
• 13.5 UCB
  • 13.5.1 Company Overview
  • 13.5.2 Neurology Portfolio
  • 13.5.3 Approved Products
  • 13.5.4 Tau-Focused Research Programs
  • 13.5.5 Clinical Development Status
• 13.6 Asceneuron
  • 13.6.1 Company Overview
  • 13.6.2 ASN Series Programs
  • 13.6.3 O-GlcNAcase Inhibition Platform
  • 13.6.4 PSP Clinical Development Activities
  • 13.6.5 Strategic Partnerships
• 13.7 TauC3 Biologics
  • 13.7.1 Company Overview
  • 13.7.2 Tau-Targeted Immunotherapy Platform
  • 13.7.3 Pipeline Candidates
  • 13.7.4 Development Strategy
• 13.8 AbbVie Inc.
  • 13.8.1 Company Overview
  • 13.8.2 Neuroscience Portfolio
  • 13.8.3 Approved Products
  • 13.8.4 Neurodegenerative Disease Research Programs
  • 13.8.5 Strategic Initiatives
• 13.9 Bristol Myers Squibb
  • 13.9.1 Company Overview
  • 13.9.2 Neuroscience Portfolio
  • 13.9.3 Approved Products
  • 13.9.4 Neurodegenerative Disease Development Programs
  • 13.9.5 Strategic Outlook
• 13.10 Biohaven Ltd.
  • 13.10.1 Company Overview
  • 13.10.2 Neurology Portfolio
  • 13.10.3 Approved Products and Pipeline Assets
  • 13.10.4 PSP-Related Development Activities
  • 13.10.5 Future Strategy

14. Future Outlook

• 14.1 Market Evolution Through Forecast Period
• 14.2 Future Treatment Paradigm Shifts
• 14.3 Emerging Disease-Modifying Therapies
• 14.4 Biomarker-Driven Patient Stratification
• 14.5 Precision Neurology Opportunities
• 14.6 Investment and Funding Trends
• 14.7 Commercialization Outlook for Late-Stage Assets
• 14.8 Strategic Recommendations

15. Methodology

• 15.1 Research Objectives
• 15.2 Study Design
• 15.3 Secondary Research Methodology
• 15.4 Primary Research Methodology
• 15.5 Epidemiology Modeling Approach
• 15.6 Market Forecasting Methodology
• 15.7 Pipeline Assessment Methodology
• 15.8 Competitive Intelligence Framework
• 15.9 Data Validation and Triangulation
• 15.10 Assumptions and Limitations
• 15.11 Abbreviations and Definitions